Crizotinib: An anaplastic lymphoma kinase inhibitor

Future Oncology

Volumn 7, Issue 8, 2011, Pages 947-953

  Gadgeel, Shirish M ^a   Bepler, Gerold ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

adenocarcinoma; ALK; anaplastic lymphoma kinase; crizotinib; HSP90; NSCLC

Indexed keywords

ALANINE AMINOTRANSFERASE; ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CISPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; PEMETREXED; PF 02341006; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG HALF LIFE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PLASMA CELL GRANULOMA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 80051731527     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.77     Document Type: Article

References (30)

1. Ardini E, Magnaghi P, Orsini P, Galvani A, Menichincheri M. Anaplastic lymphoma kinase: Role in specific tumours, and development of small molecule inhibitors for cancer therapy. Cancer Lett. 299(2), 81-94 (2010).
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2010).
3. Higgins MJ, Ettinger DS. Chemotherapy for lung cancer: The state of the art in 2009. Expert Rev. Anticancer Ther. 9(10), 1365-1378 (2009).
4. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153), 561-566 (2007). nn First description of the EML4-ALK rearrangement and its biological relevance in lung cancer. (Pubitemid 47206930)
5. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27(26), 4247-4253 (2009). nn First description of the clinical features of patients with lung cancer that harbor the EML4-ALK rearrangement.
6. Rodig SJ, Mino-Kenudson M, Dacic S et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer Res. 15(16), 5216-5223 (2009).
7. Cortes J, Hochhaus A, Hughes T, Kantarjian H. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J. Clin. Oncol. 29(5), 524-531 (2011).
8. Ganjoo KN, Patel S. Current and emerging pharmacological treatments for gastrointestinal stromal tumour. Drugs 71(3), 321-330 (2011).
9. Kwak EL, Camidge DR, Clark J et al. Clinical activity observed in a Phase I dose escalation trial of an oral c-Met and ALK inhibitor, PF-02341066. J. Clin. Oncol. 27(15 Suppl.), Abstract 3509 (2009).
10. Li C, Alvey C, Bello A, Wilner KD, Tan W. Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J. Clin. Oncol. 29(Suppl.), Abstract E13065 (2011).
11. Costa DB, Kobayashi S, Pandya SS et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J. Clin. Oncol. 29(15), E443-E445 (2011).
12. Zou HY, Li Q, Lee JH et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67(9), 4408-4417 (2007). (Pubitemid 46815090)
13. Christensen JG, Zou HY, Arango ME et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 6(12 Pt 1), 3314-3322 (2007).
14. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: A new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J. Thorac. Oncol. 4(12), 1450-1454 (2009).
15. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693-1703 (2010). nn First publication describing the clinical activity of crizotinib in ALK-rearranged non-small-cell lung cancer patients.
16. Camidge DR, Bang Y, Kwak EL et al. Progression-free survival (PFS) from a Phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 29(Suppl.), Abstract 2501 (2011).
17. Crino L, Kim D, Riely GJ et al. Initial Phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J. Clin. Oncol. 29(Suppl.), Abstract 7514 (2011).
18. Shaw AT, Yeap BY, Solomon BJ et al. Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. J. Clin. Oncol. 29(Suppl.), Abstract 7507 (2011).
19. Giaccone G, Wang Y. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat. Rev. DOI: 10.1016/j.ctrv.2011.01.003 (2011) (Epub ahead of print).
20. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105(7), 2640-2653 (2005). (Pubitemid 40446252)
21. Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363(18), 1734-1739 (2010).
22. Katayama R, Khan TM, Benes C et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl Acad. Sci. USA 108(18), 7535-7540 (2011). n Important publication detailing the resistance mechanisms to crizotinib.
23. Sakamoto H, Tsukaguchi T, Hiroshima S et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19(5), 679-690 (2011).
24. Sasaki T, Okuda K, Zheng W et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 70(24), 10038-10043 (2010).
25. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10(8), 537-549 (2010).
26. Sequist LV, Gettinger S, Senzer NN et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J. Clin. Oncol. 28(33), 4953-4960 (2010).
27. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N. Engl. J. Med. 364(8), 775-776 (2011).
28. Butrynski JE, D'Adamo DR, Hornick JL et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363(18), 1727-1733 (2010).
29. Ou SH, Kwak EL, Siwak-Tapp C et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J. Thorac. Oncol. 6(5), 942-946 (2011).
30. Lennerz JK, Kwak EL, Michael M et al. Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification. J. Clin. Oncol. 29(Suppl.), Abstract 4130 (2011).